Convertible Note Modification and Default Waiver AgreementConvertible Note Modification and Default Waiver Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Note Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between Medical Marijuana, Inc., an Oregon corporation ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company"), with reference to the following facts.
SETTLEMENT AGREEMENTSettlement Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Settlement Agreement (the “Agreement”) is entered into as of January 23, 2023 (the “Effective Date”) by and between Axim Biotechnologies, Inc. ("AXIM" or the "Company") and John W. Huemoeller II (the "Executive"), with reference to the following facts:
Convertible Notes Modification and Default Waiver AgreementConvertible Notes Modification and Default Waiver Agreement • January 27th, 2023 • Axim Biotechnologies, Inc. • Pharmaceutical preparations • California
This Convertible Notes Modification and Default Waiver Agreement (the "Agreement") is entered into as of January 23, 2023 (the "Effective Date") by and between TL-66 LLC, a California limited liability company ("Creditor") and Axim Biotechnologies, Inc., a Nevada corporation ("AXIM" or the "Company") and Sapphire Biotechnologies, Inc, a Delaware corporation, wholly owned subsidiary of AXIM ("Sapphire"), with reference to the following facts.
